MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells. The license gives Geron exclusive rights to the technology for therapeutic applications, and will enhance Geron’s program to develop cell replacement therapies for orthopedic indications such as osteoarthritis, a disease affecting 27 million people in the U.S. Financial terms of the license agreement were not disclosed.
